Page 14: showes D9901 more sick patients in the placebo arm (Gleasson <= 6) those <=6 Gleason Patients are the survivers. (34% versus 11%) no wonder, that Provenge produced survival. Page 33: showes D9902A slightly more sick patients (nearly equal) in the Provenge arm, here Provenge worked practically not.
That also explains why Gold said recently, he had a short look into the randomisation of 9902B what I did not understand at all.
It explains why it takes so long to find 60 more patients for 6602B when 27000 per year die on prostate cancer, Gold playes on time.
My concern was from the beginning on, that the Provenge and the Placebo arm are not properly randomized. With such a primitive method FDA cannot be fooled.
Probably that was the reason why Small did not turn up at the meeting. Not to be confronted with that Question.
If the board would not have voted so positive, Provenge would even not have got a CR letter. But look at the board members, mainly surgeons and orthopedes. They are not the once who go into the theory deeply, the are mainly tired from their work.
What I also realized: D9901 and D9902 A where finished in 09/2004 why suddenly in 10/2006 go for fast track approval? there are 2 years in between. Does it take so long to to come to a conclution?
It also explains Gold's insider sale. He knew how weak his data was.
It explains why Nuovenge was stopped, the data was to weak, there was only a "chance" to get hopefully away with it once.
That the German company stopped the trials with immuno therapie, it all fits into that picture. That is why all this shortselling happend.
I want to apollogize for all the e-mails I have written, I was wrong.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.